Perspective Therapeutics Inc (CATX)
0.548
+0.01
(+1.48%)
USD |
NYAM |
Jun 07, 15:10
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 153.51M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 92.17% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 11.37 |
| Price to Book Value | 1.301 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0152 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 91.85% |
Profile
| Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. |
| URL | https://perspectivetherapeutics.com |
| Investor Relations URL | https://isoray.com/investor-center/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Aug. 14, 2023 (est.) |
| Last Earnings Release | May. 16, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. |
| URL | https://perspectivetherapeutics.com |
| Investor Relations URL | https://isoray.com/investor-center/ |
| HQ State/Province | Washington |
| Sector | Healthcare |
| Industry | Medical Devices |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Aug. 14, 2023 (est.) |
| Last Earnings Release | May. 16, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |